A Phase 1, Open Label, Randomized, Three-treatment, Three-sequence, Three-period, Crossover Adhesion Performance and Pharmacokinetic Study of Lidocaine Topical System 1.8% in Healthy, Adult Subjects Under Normal and Two Water Stress Conditions
Latest Information Update: 10 Mar 2021
At a glance
- Drugs Lidocaine (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Scilex Pharmaceuticals
- 10 Mar 2021 New trial record